ClinicalTrials.gg
RecruitingNCT07501234MITRA-EFSUpdated Mar 30, 2026

Safety and Feasibility Study of the MitraFix® Transcatheter Mitral Valve System

An interventional study of MitraFix® Transcatheter Mitral Valve System in Mitral Regurgitation (MR), sponsored by Mitrassist Lifesciences Limited Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Mitrassist Lifesciences Limited Co., Ltd. · Not applicable, Interventional, and Device feasibility

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Mitral Valve Insufficiency with a site in China — 44 open to participants now, 46 under way, none of them phase 3. Mitral Valve Insufficiency · China.

Planned enrollment
40th of 40
5 · median 127
Started
2026
with 7 others
No phase
36 of 57
29 open now
Primary completion
2028-03
later than 35 of 45 live
Registered
48th of 57
by date

Among the 57 studies in Mitral Valve Insufficiency with a site in China, this one is the 40th largest by planned enrollment of the 40 interventional ones that give a count, is one of 8 that started in 2026, is one of 36 with no phase, reaches primary completion later than 35 of the 45 other live ones, and was the 48th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

44 of the 57 studies in Mitral Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Mitral Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

The goal of this early feasibility clinical trial is to test a new device called the MitraFix® Transcatheter Mitral Valve System. It aims to learn if the device is safe and if it can help adults who have a severe leaky heart valve (mitral regurgitation). This study is for people who are at high risk for traditional open-heart surgery.

The main questions it aims to answer are:

Is the MitraFix system safe for participants? Can the device be successfully placed in the heart? Does the device help reduce the valve leak and improve daily life?

Participants will:

Receive the MitraFix valve through a small tube inserted into a vein in the leg.

Visit the clinic for heart tests, walking tests, and health checks for up to one year after the procedure.

03

Conditions studied

  • Mitral Regurgitation (MR)

Keywords

  • MitraFix
  • Transcatheter Mitral Valve Replacement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe or severe (≥3+) mitral regurgitation.
  • Age ≥ 18 years.
  • Patients at high risk for traditional open-heart surgery, defined as: STS mortality risk for mitral valve replacement ≥ 8%; OR presence of 2 or more frailty indices; OR presence of 2 or more major organ dysfunctions that cannot be improved post-operatively; OR other comorbidities or factors making them unsuitable for surgery.
  • Anatomically suitable for transcatheter MitraFix® system implantation via a transfemoral-transseptal approach as assessed by the investigator; the transfemoral-transseptal access route meets the requirements of the delivery system.
  • Able to understand the study purpose, voluntarily participate, sign the form, and willing to accept relevant examinations and clinical follow-ups.

Exclusion criteria

Exclusion Criteria:

  • Severe mitral stenosis.
  • Severe calcification of mitral leaflets and/or annulus; anatomical structures of the mitral valve apparatus (e.g., papillary muscles) unsuitable for device implantation.
  • High risk of left ventricular outflow tract obstruction (LVOTO) based on pre-operative CT/TEE planning (estimated neo-LVOT \< 150 mm²), which cannot be avoided by procedural optimization.
  • Presence of previous implants in the mitral position (surgical bioprosthetic or mechanical valves, surgical annuloplasty rings, etc.).
  • Infective endocarditis or evidence of active infection.
  • Stroke or (TIA) within 90 days.
  • Severe untreated coronary artery disease or acute myocardial infarction within 90 days; or percutaneous coronary intervention (PCI)/coronary stent implantation within 90 days.
  • Severe pulmonary hypertension (resting PASP > 70 mmHg, assessed as irreversible).
  • Severe right ventricular dysfunction: Tricuspid Annular Plane Systolic Excursion (TAPSE) \< 17 mm.
  • Concomitant tricuspid valve, aortic valve, or severe great vessel disease requiring surgical or interventional treatment.
  • (LVEF) \< 30%.
  • Extreme frailty preventing tolerance of the procedure, or in a state of shock requiring circulatory support.
  • Implantation of CRT, CRT-D, or implantable cardioverter-defibrillator (ICD) within 30 days.
  • Chronic dialysis or expected need for long-term dialysis; or severe renal impairment (e.g., \< 30 mL/min/1.73m²) unable to undergo perioperative dialysis.
  • Documented coagulopathy or severe hematological disorders (e.g., count \< 50×10\^9/L, active bleeding), or history of heparin-induced thrombocytopenia (HIT).
  • to anticoagulant/antiplatelet therapy that cannot be substituted or bridged.
  • Echocardiographic evidence of any intracardiac mass, or thrombus in the left ventricle or left atrium (including left atrial appendage).
  • Contraindications to transesophageal echocardiography (TEE).
  • Severe allergy to iodine contrast media, nitinol, bovine-derived materials, or other device materials that remains intolerable despite premedication.
  • \< 12 months.
  • Pregnant or breastfeeding women.
  • Unsuitable for the transfemoral-transseptal approach (e.g., femoral vein diameter, calcification, tortuosity, or atrial septum/left atrial anatomy not meeting delivery system requirements).
  • Participation in another clinical study of an device or drug within 3 months prior to screening that may interfere with this study.
  • Any other conditions deemed unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    MitraFix System

    Participants with moderate-to-severe or severe (≥3+) mitral regurgitation who are at high surgical risk will receive the MitraFix® Transcatheter Mitral Valve System.

    Device: MitraFix® Transcatheter Mitral Valve System

Interventions

  • DeviceMitraFix® Transcatheter Mitral Valve System

    The MitraFix® Transcatheter Mitral Valve System is implanted via a transfemoral-transseptal approach.

06

What researchers measure

Primary outcomes

  1. Device Success Rate

    evice success is defined as the patient being alive and free from stroke, with the implanted valve in the intended position and functioning properly, without the need for re-operation or re-intervention due to device-related complications.

    Time frame: 30 days post-procedure

Secondary outcomes

  1. Technical Success Rate

    Percentage of participants achieving technical success, defined as successful access, delivery, and deployment of the device, and successful retrieval of the delivery system.

    Time frame: Intra-operative (At the time of procedure)

  2. Procedural Success Rate

    Percentage of participants achieving procedural success, typically defined as technical success without the occurrence of major device- or procedure-related serious adverse events.

    Time frame: 30 days post-procedure

  3. Valve Performance Assessment

    Evaluated by echocardiography, including the severity of residual mitral regurgitation, transvalvular pressure gradient, and the presence/severity of paravalvular leak.

    Time frame: Up to 12 months post-procedure

  4. Change in New York Heart Association (NYHA) Functional Class

    Assessment of clinical improvement in heart failure symptoms based on the NYHA classification (Class I to IV, where a lower class indicates better function).

    Time frame: Up to 12 months post-procedure

  5. Change in Quality of Life Assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score

    Quality of life is evaluated using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ Overall Summary Score ranges from 0 to 100. Higher scores indicate fewer symptoms and better health-related quality of life.

    Time frame: Up to 12 months post-procedure

  6. Change in 6-Minute Walk Distance

    The change in the total distance (in meters) a participant can walk on a flat surface in 6 minutes, used to evaluate exercise capacity.

    Time frame: Up to 12 months post-procedure

  7. Rate of Hospitalization for Heart Failure

    Number of participants requiring hospital admission or an emergency/urgent care visit for the treatment of worsening heart failure.

    Time frame: Up to 12 months post-procedure

  8. Incidence of Major Adverse Events (MAEs)

    Number of participants experiencing major adverse events, such as all-cause mortality, stroke, life-threatening bleeding, or acute kidney injury.

    Time frame: Up to 12 months post-procedure

  9. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants experiencing any device-related or procedure-related adverse events and serious adverse events.

    Time frame: Up to 12 months post-procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2028, 24 months later.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 24 months is below that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 30, 2026
StartEst.
Mar 23, 2026
Primary completionEst.
Mar 23, 2028
CompletionEst.
Oct 23, 2028
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07501234
Lead sponsor
Mitrassist Lifesciences Limited Co., Ltd.
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Mar 23, 2026 (estimated)
Primary completion
Mar 23, 2028 (estimated)
Completion
Oct 23, 2028 (estimated)
Last update
Mar 30, 2026

Study contacts

NaXin Di
Contact
tina.ti@mitrassist.com.cn
021-69925338

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion